IND SWIFT LA share price has zoomed 14% and is presently trading at Rs 368.7.
Meanwhile, the BSE HEALTHCARE index is at 51,192.8 (up 0.6%).
Among the top gainers in the BSE HEALTHCARE index today are COHANCE LIFESCIENCES (up 3.7%) and Divis Laboratories (up 3.5%).
J.B.Chemicals (down 3.7%) and GRANULES INDIA (down 2.6%) are among the top losers today.
Over the last one year, IND SWIFT LA has moved up from Rs 96.7 to Rs 368.7, registering a gain of Rs 272.0 (up 281.4%).
On the other hand, the BSE HEALTHCARE index has moved up from 44,815.9 to 51,192.8, registering a gain of 14.2% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were LAURUS LABS (up 115.9%), GRANULES INDIA (up 78.6%) and Aurobindo Pharma (up 52.1%).
Discover: Where the opportunities are emerging for the next 3-5 years
The BSE Sensex is at 77,685.2 .
The top gainers among the BSE Sensex today are Kotak Bank (up 3.4%) and Axis Bank (up 1.4%). The most traded stocks in the BSE Sensex are Kotak Bank and HDFC Bank.
In the meantime, NSE Nifty is at 24,283.9 (down 0.2%). Tech Mahindra and Shriram Transport are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved down from 81,635.9 to 77,685.2, registering a loss of 3,950.7 points (down 4.8%).
IND SWIFT LA net profit grew 184.1% YoY to Rs 246 million for the quarter ended June 2026, compared to a profit of Rs 86 million a year ago. Net sales rose 20.9% to Rs 1,915 million during the period as against Rs 1,583 million in April-June 2025.
For the year ended March 2025, IND SWIFT LA reported 40.6% decrease in net profit to Rs 2,505 million compared to net profit of Rs 4,215 million during FY24. Revenue of the company fell 56.1% to Rs 5,617 million during FY25.
The current Price to earnings ratio of IND SWIFT LA, based on rolling 12 month earnings, stands at 56.0.
Image source: ipopba/www.istockphoto.com
Equitymaster requests your view! Post a comment on "IND SWIFT LA Gains 14%; BSE HEALTHCARE Index Up 0.6%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!